Bluebird bio Inc ( (BLUE) ) has released its Q3 earnings. Here is a breakdown of the information Bluebird bio Inc presented to its investors.

Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Welcome to bluebird bio's third quarter 2024 results conference call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

bluebird bio is to ask regulators to restart clinical studies of its LentiGlobin for sickle cell disease, after an investigation concluded that a case of acute myeloid leukaemia (AML) was "very ...

US biotech bluebird bio has announced plans to split into two ... While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been ...

Bluebird Bio (BLUE) Company Description: bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE ...